Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
Frequently asked questions
What sector does Cybin Inc (CYBN) operate in?
Cybin Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Cybin Inc (CYBN) current stock price?
As of the latest data, Cybin Inc stock price is $5.25, with a previous close of $5.25.
What is Cybin Inc (CYBN) current market capitalization?
Cybin Inc market cap is approximately 261.69 million.
What is Cybin Inc (CYBN) Earnings Per Share (EPS)?
The trailing EPS is -$3.77, and the forward EPS is -$4.03.
Does Cybin Inc (CYBN) pay dividends?
No. Cybin Inc does not pay a dividend.
What is Cybin Inc (CYBN) beta (volatility) score?
Cybin Inc has a beta of 0.793, indicating lower volatility than the overall market.
